HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Manna, S. K. Articles by Aggarwal, B. B. Search for Related Content PubMed PubMed Citation Articles by Manna, S. K. Articles by Aggarwal, B. B.

Vesnarinone Suppresses TNF-Induced Activation of NF-B, c-Jun Kinase, and Apoptosis¹

Cytokine Research Laboratory, Department of Bioimmunotherapy, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030

Vesnarinone, a synthetic quinolinone derivative used in the treatment of cardiac failure, exhibits immunomodulatory, anti-inflammatory, and cell growth regulatory properties. The mechanisms underlying these properties are not understood, but due to the critical role of nuclear transcription factor NF-B in these responses, we hypothesized that vesnarinone must modulate NF-B activation. We investigated the effect of vesnarinone on NF-B activation induced by inflammatory agents. Vesnarinone blocked TNF-induced activation of NF-B in a concentration- and time-dependent manner. This effect was mediated through inhibition of phosphorylation and degradation of IB, an inhibitor of NF-B. The effects of vesnarinone were not cell type specific, as it blocked TNF-induced NF-B activation in a variety of cells. NF-B-dependent reporter gene transcription activated by TNF was also suppressed by vesnarinone. The TNF-induced NF-B activation cascade involving TNF receptor 1-TNF receptor associated death domain-TNF receptor associated factor 2 NF-B-inducing kinase-IKK was interrupted at the TNF receptor associated factor 2 and NF-B-inducing kinase sites by vesnarinone, thus suppressing NF-B reporter gene expression. Vesnarinone also blocked NF-B activation induced by several other inflammatory agents, inhibited the TNF-induced activation of transcription factor AP-1, and suppressed the TNF-induced activation of c-Jun N-terminal kinase and mitogen-activated protein kinase kinase. TNF-induced cytotoxicity, caspase activation, and lipid peroxidation were also abolished by vesnarinone. Overall, our results indicate that vesnarinone inhibits activation of NF-B and AP-1 and their associated kinases. This may provide a molecular basis for vesnarinone’s ability to suppress inflammation, immunomodulation, and growth regulation.

This article has been cited by other articles:

				T. Takao, C. Kumagai, N. Hisakawa, R. Matsumoto, and K. Hashimoto Effect of 17{beta}-estradiol on tumor necrosis factor-{alpha}-induced cytotoxicity in the human peripheral T lymphocytes J. Endocrinol., January 1, 2005; 184(1): 191 - 197. [Abstract] [Full Text] [PDF]

				T. Kondo, Y. Suzuki, T. Kitano, K. Iwai, M. Watanabe, H. Umehara, N. Daido, N. Domae, M. Tashima, T. Uchiyama, et al. Vesnarinone Causes Oxidative Damage by Inhibiting Catalase Function through Ceramide Action in Myeloid Cell Apoptosis Mol. Pharmacol., March 1, 2002; 61(3): 620 - 627. [Abstract] [Full Text] [PDF]